Identifying the Best Candidate for Radical Prostatectomy in High-Risk Prostate Cancer

  • Jung Jun Kim
  • Sung Kyu HongEmail author


Radical prostatectomy (RP) has been regarded as one of the gold standard therapeutic option for localized or locally advanced prostate cancer patients. However, the surgery for localized low-risk prostate cancer may not be the standard anymore due to the concern of overtreatment recently. On the other hand, regarding the treatment of high-risk or locally advanced prostate cancer, the role of surgery started to extend their territory.


  1. 1.
    Yossepowitch O, Eggener SE, Bianco FJ, Carver BS, Serio A, Scardino PT, et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol. 2007;178(2):493–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, Partin AW. Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol. 2004;172(5):1835–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Gerber G, Thisted R, Chodak G, Schroder F, Frohmuller H, Scardino P, et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol. 1997;32(4):385–90.PubMedGoogle Scholar
  4. 4.
    Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, Fieuws S, et al. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. Eur Urol. 2015;67(1):157–64.PubMedCrossRefGoogle Scholar
  5. 5.
    Gallina A, Chun FK-H, Briganti A, Shariat SF, Montorsi F, Salonia A, et al. Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. Eur Urol. 2007;52(1):98–105.PubMedCrossRefGoogle Scholar
  6. 6.
    Joniau S, Hsu C-Y, Lerut E, Van Baelen A, Haustermans K, Roskams T, et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol. 2007;51(2):388–96.PubMedCrossRefGoogle Scholar
  7. 7.
    Van Poppel H, Ameye F, Oyen R, Van De Voorde W, Baert L. Accuracy of combined computerized tomography and fine needle aspiration cytology in lymph node staging of localized prostatic carcinoma. J Urol. 1994;151(5):1310–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.PubMedCrossRefGoogle Scholar
  9. 9.
    Van Poppel H, Vekemans K, Da Pozzo L, Bono A, Kliment J, Montironi R, et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer. 2006;42(8):1062–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Van Poppel H. Surgery for clinical T3 prostate cancer. Eur Urol Suppl. 2005;4(4):12–4.CrossRefGoogle Scholar
  11. 11.
    Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde W, Baert L. Radical prostatectomy can provide a cure for well–selected clinical stage T3 prostate cancer. Eur Urol. 2000;38(4):372–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95(6):751–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Briganti A, Karakiewicz PI, Chun FK-H, Gallina A, Salonia A, Zanni G, et al. Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. Eur Urol. 2007;51(6):1573–81.PubMedCrossRefGoogle Scholar
  14. 14.
    Donohue JF, Bianco FJ, Kuroiwa K, Vickers AJ, Wheeler TM, Scardino PT, et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol. 2006;176(3):991–5.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Manoharan M, Bird V, Kim S, Civantos F, Soloway M. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of≥8. BJU Int. 2003;92(6):539–44.PubMedCrossRefGoogle Scholar
  16. 16.
    Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol. 2003;169(1):157–63.PubMedCrossRefGoogle Scholar
  17. 17.
    Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer. 2006;107(6):1265–72.PubMedCrossRefGoogle Scholar
  18. 18.
    Mian BM, Troncoso P, Okihara K, Bhadkamkar V, Johnston D, Reyes AO, et al. Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol. 2002;167(4):1675–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol. 2002;167(1):117–22.PubMedCrossRefGoogle Scholar
  20. 20.
    Thompson IM. Survival after radical retropubic prostatectomy of men and clinically localized high grade carcinoma of the prostate. Cancer. 1996;78(1):181.PubMedCrossRefGoogle Scholar
  21. 21.
    Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Sakr W, Grignon D, et al. Role of radical prostatectomy in patients with prostate cancer of high Gleason score. Prostate. 1999;39(1):60–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Serni S, Masieri L, Minervini A, Lapini A, Nesi G, Carini M. Cancer progression after anterograde radical prostatectomy for pathologic Gleason score 8 to 10 and influence of concomitant variables. Urology. 2006;67(2):373–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994;152(5):1843–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Hsu C-Y, Joniau S, Oyen R, Roskams T, Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol. 2007;51(1):121–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Joniau S, Hsu C-Y, Gontero P, Spahn M, Van Poppel H. Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors. Scand J Urol Nephrol. 2012;46(3):164–71.PubMedCrossRefGoogle Scholar
  26. 26.
    Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int. 2012;110(11):1709–13.PubMedCrossRefGoogle Scholar
  27. 27.
    Johnstone PA, Ward KC, Goodman M, Assikis V, Petros JA. Radical prostatectomy for clinical T4 prostate cancer. Cancer. 2006;106(12):2603–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Spahn M, Joniau S, Gontero P, Fieuws S, Marchioro G, Tombal B, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol. 2010;58(1):1–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, et al. The role of radical prostatectomy and lymph node dissection in lymph node–positive prostate cancer: a systematic review of the literature. Eur Urol. 2014;66(2):191–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Frohmüller H, Theiss M, Manseck A, Wirth M. Survival and quality of life of patients with stage D1 (T1-3 pN1-2 MO) prostate cancer. Eur Urol. 1995;27:202–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol. 2007;178(3):864–71.PubMedCrossRefGoogle Scholar
  33. 33.
    Moschini M, Briganti A, Murphy CR, Bianchi M, Gandaglia G, Montorsi F, et al. Outcomes for patients with clinical lymphadenopathy treated with radical prostatectomy. Eur Urol. 2016;69(2):193–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Engel J, Bastian PJ, Baur H, Beer V, Chaussy C, Gschwend JE, et al. Survival benefit of radical prostatectomy in lymph node–positive patients with prostate cancer. Eur Urol. 2010;57(5):754–61.PubMedCrossRefGoogle Scholar
  35. 35.
    Verhagen PC, Schröder FH, Collette L, Bangma CH. Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol. 2010;58(2):261–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol. 2003;169(3):849–54.PubMedCrossRefGoogle Scholar
  37. 37.
    Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, et al. Radical prostatectomy, external beam radiotherapy<72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58(1):25–33.PubMedCrossRefGoogle Scholar
  38. 38.
    Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011;117(13):2883–91.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, et al. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer. BJU Int. 2012;110(8):1116–21.PubMedCrossRefGoogle Scholar
  40. 40.
    Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, Yamada Y, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010;28(9):1508–13.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Aizer AA, James BY, Colberg JW, McKeon AM, Decker RH, Peschel RE. Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol. 2009;93(2):185–91.PubMedCrossRefGoogle Scholar
  42. 42.
    Ellis CL, Partin AW, Han M, Epstein JI. Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosis. J Urol. 2013;190(6):2068–73.PubMedCrossRefGoogle Scholar
  43. 43.
    Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010;116(22):5226–34.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Hoffman RM, Koyama T, Fan K-H, Albertsen PC, Barry MJ, Goodman M, et al. Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst. 2013;105(10):711–8.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Kibel AS, Ciezki JP, Klein EA, Reddy CA, Lubahn JD, Haslag-Minoff J, et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol. 2012;187(4):1259–65.PubMedCrossRefGoogle Scholar
  46. 46.
    Nepple KG, Stephenson AJ, Kallogjeri D, Michalski J, Grubb RL, Strope SA, et al. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol. 2013;64(3):372–8.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ. 2014;348:g1502.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, et al. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol. 2012;61(3):584–92.PubMedCrossRefGoogle Scholar
  49. 49.
    Pardo Y, Guedea F, Aguiló F, Fernández P, Macías V, Mariño A, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol. 2010;28(31):4687–96.PubMedCrossRefGoogle Scholar
  50. 50.
    Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61.PubMedCrossRefGoogle Scholar
  51. 51.
    Ferrer M, Guedea F, Suárez JF, de Paula B, Macías V, Mariño A, et al. Quality of life impact of treatments for localized prostate cancer: Cohort study with a 5year follow-up. Radiother Oncol. 2013;108(2):306–13.PubMedCrossRefGoogle Scholar
  52. 52.
    Gay HA, Michalski JM, Hamstra DA, Wei JT, Dunn RL, Klein EA, et al. Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. Urology. 2013;82(6):1363–9.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306(21):2359–66.PubMedCrossRefGoogle Scholar
  54. 54.
    Levine GN, D’amico AV, Berger P, Clark PE, Eckel RH, Keating NL, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60(3):194–201.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Hamstra DA, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff AL, et al. Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. Int J Radiat Oncol Biol Phys. 2013;86(3):546–53.PubMedCrossRefGoogle Scholar
  56. 56.
    Resnick MJ, Koyama T, Fan K-H, Albertsen PC, Goodman M, Hamilton AS, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368(5):436–45.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Froehner M, Koch R, Litz RJ, Hakenberg OW, Wirth MP. Which patients are at the highest risk of dying from competing causes ≤0 years after radical prostatectomy? BJU Int. 2012;110(2):206–10.PubMedCrossRefGoogle Scholar
  58. 58.
    Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011;29(10):1335–41.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988–2006. Eur Urol. 2011;59(1):88–95.PubMedCrossRefGoogle Scholar
  60. 60.
    Eastham JA, Evans CP, Zietman A. What is the optimal management of high risk, clinically localized prostate cancer? Urol Oncol. 2010;28:557–67. Elsevier.PubMedCrossRefGoogle Scholar
  61. 61.
    Yossepowitch O, Eastham JA. Role of radical prostatectomy in the treatment of high-risk prostate cancer. Curr Prostate Rep. 2008;6(3):107–14.CrossRefGoogle Scholar
  62. 62.
    Hamilton AS, Albertsen PC, Johnson TK, Hoffman R, Morrell D, Deapen D, et al. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int. 2011;107(4):576–84.PubMedCrossRefGoogle Scholar
  63. 63.
    Miocinovic R, Berglund RK, Stephenson AJ, Jones JS, Fergany A, Kaouk J, et al. Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. Urology. 2011;77(4):946–50.PubMedCrossRefGoogle Scholar
  64. 64.
    Walz J, Joniau S, Chun FK, Isbarn H, Jeldres C, Yossepowitch O, et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int. 2011;107(5):765–70.PubMedCrossRefGoogle Scholar
  65. 65.
    Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology. 2010;76(3):710–4.PubMedCrossRefGoogle Scholar
  66. 66.
    Mohler JL, Armstrong AJ, Bahnson RR, D’Amico AV, Davis BJ, Eastham JA, et al. Prostate cancer, version 1.2016. J Natl Compr Canc Netw. 2016;14(1):19–30.PubMedCrossRefGoogle Scholar
  67. 67.
    Öbek C, Doğanca T, Demirci E, Ocak M, Kural AR, Yıldırım A, et al. The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1–7.CrossRefGoogle Scholar
  68. 68.
    Budäus L, Leyh-Bannurah S-R, Salomon G, Michl U, Heinzer H, Huland H, et al. Initial experience of 68 Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69(3):393–6.PubMedCrossRefGoogle Scholar
  69. 69.
    Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, et al. 68 Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol. 2016;70(4):553–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of 68 gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195(5):1436–43.PubMedCrossRefGoogle Scholar
  71. 71.
    Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int. 2017;119(2):209–15.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Seoul National University Bundang HospitalSeongnamSouth Korea
  2. 2.Seoul National UniversitySeoulSouth Korea

Personalised recommendations